Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Searches for diabetes, heart conditions, and metabolism-related risks are rising sharply, with Tier 2 cities outpacing metros in specialist consultations
Sharp increase in diabetes, hypertension and fatty liver in 30–50 age group
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Subscribe To Our Newsletter & Stay Updated
